- Amended Quarterly Report (10-Q/A)
06 Septiembre 2012 - 3:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q/A
Amendment No. 1
(Mark One)
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
For the quarterly period ended June 30, 2012
Or
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Commission File Number 000-33009
MEDCATH
CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of
incorporation or
organization)
|
|
56-2248952
(IRS Employer
Identification No.)
|
10720 Sikes Place
Charlotte, North Carolina 28277
(Address of principal executive offices,
including zip code)
(704) 815-7700
(Registrants telephone number, including area code)
Indicate by check mark whether
the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
x
No
¨
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files). Yes
x
No
¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
x
|
|
|
|
|
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
¨
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes
¨
No
x
As of August 8, 2012, there were 20,350,790 shares of $0.01 par value common stock outstanding.
EXPLANATORY NOTE
This Amendment No. 1 to the Quarterly Report on Form 10-Q/A (the
Amendment
) amends the Quarterly Report on Form 10-Q of MedCath Corporation (the
Company
) for the
quarter ended June 30, 2012 (the
Original Filing
), that was originally filed with the U.S. Securities and Exchange Commission on August 9, 2012. The Amendment is being filed to submit Exhibit 101. The Amendment revises
the exhibit index included in Part II, Item 6 of the Original Filing and Exhibit 101 (XBRL interactive data) is included as an exhibit to the Amendment.
In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (
Exchange Act
), new certifications by the Companys principal executive officer and
principal financial officers are filed as exhibits hereto.
Except as described above, the Amendment does not modify or update the disclosures
presented in, or exhibits to, the Original Filing in any way. Those sections of the Original Filing that are unaffected by the Amendment are not included herein. The Amendment continues to speak as of the date of the Original Filing. Furthermore,
the Amendment does not reflect events occurring after the filing of the Original Filing. Accordingly, the Amendment should be read in conjunction with the Original Filing, as well as the Companys other filings made with the SEC pursuant to
Section 13(a) or 15(d) of the Exchange Act subsequent to the filing of the Original Filing
2
Item 6. Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
31.1
|
|
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
31.2
|
|
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
101
|
|
The following materials from the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 formatted in Extensible Business Reporting Language (XBRL): (i) the
Statement of Net Assets, (ii) the Statement of Changes in Net Assets, (iii) Consolidated Statement of Cash Flows and (iv) related notes.
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MEDCATH CORPORATION
|
|
|
|
|
Dated: September 6, 2012
|
|
|
|
By:
|
|
/s/ JAMES A. PARKER
|
|
|
|
|
|
|
James A. Parker
|
|
|
|
|
|
|
President and Chief Executive Officer
(principal executive officer)
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ LORA RAMSEY
|
|
|
|
|
|
|
Lora Ramsey
|
|
|
|
|
|
|
Vice President and Chief Financial Officer
(principal financial and accounting officer)
|
4
INDEX TO EXHIBITS
|
|
|
Exhibit
No.
|
|
Description
|
|
|
31.1
|
|
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
31.2
|
|
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
101
|
|
The following materials from the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 formatted in Extensible Business Reporting Language (XBRL): (i) the
Statement of Net Assets, (ii) the Statement of Changes in Net Assets, (iii) Consolidated Statement of Cash Flows and (iv) related notes.
|
5
Medcath (NASDAQ:MDTH)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Medcath (NASDAQ:MDTH)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024